Mr. Virsik has been ESSA’s Executive Vice President and Chief Operating Officer since 2016. Mr. Virsik has over 20 years of experience in corporate development, strategy, new product planning, alliance management, and finance. Prior to joining ESSA, Mr. Virsik was Senior Vice President, Corporate Development for XenoPort (acquired by Arbor Pharmaceuticals), where he led licensing, strategy, new product planning and alliance management. Mr. Virsik also worked in corporate development for Gilead Sciences, where he was involved in building Gilead’s HIV franchise through the acquisition of Triangle Pharmaceuticals and the licensing of Vitekta® (elvitegravir). Earlier in his career, Mr. Virsik worked at J.P. Morgan in the biotechnology equity research group, as a consultant for Ernst and Young, and in research and development at Genentech. Mr. Virsik received an M.B.A. from the Kellogg Graduate School of Management at Northwestern University, an M.S. in Microbiology from the University of Michigan, Ann Arbor, and a B.A. in Molecular and Cellular Biology from the University of California, Berkeley.

• 

  Executive Vice President in ESSA Pharmaceuticals

  Developing the Next Generation of Treatments for Prostate Cancer

• 

  Chief Operating Officer (COO) in ESSA Pharmaceuticals

  Developing the Next Generation of Treatments for Prostate Cancer